AT-101 is under clinical development by Abclon and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AT-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AT-101 is under development for the treatment of blood cancers like B cell leukemia, relapsed or refractory CD19 positive acute lymphoblastic leukemia, lymphoma, relapsed or refractory B-cell non-Hodgkin's lymphoma. The drug candidate comprises of CD19-CAR -T cells coupled with CD19 antibody. It is administered through parenteral route.
Abclon is a biotechnology company that offers drug development and manufacturing services. It discover and develops antibody drugs for the treatment of stomach and lung cancer. Abclon is headquartered in Seoul, South Korea.
For a complete picture of AT-101’s drug-specific PTSR and LoA scores, buy the report here.